All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Currently, Apellis Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy now. This doesn't mean APLS will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems
Knowing when to sell a stock is even harder than knowing when to buy it. Trading strategies prevent us from making impulsive decisions based on our moods or the buzz surrounding the market. When selling, as well as buying, detailed setups are very easy to follow and are only applicable for selling shares you already own, not for selling short APLS stock
A guiding principle is that you should not mantain an open trade that produces greater losses than those expected upon purchase. The moment to sell shares should always be dictated by the stop-loss (automatic or manual)
Currently, Apellis Pharmaceuticals stock doesn't match any of our preferred sell setups, so if you hold Apellis Pharmaceuticals stock and your operation is in profit probably is not time to sell now
Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal
In the last month, just one rating was published for Apellis Pharmaceuticals
|Aug 31st, 2020|
|Stifel Nicolaus||Strong buy|
Since in late July, Apellis Pharmaceuticals has been drawing an uptrend that so far marked a gorgeous 18.56%. Rising tops and bottoms can be seen easily on a chart and how price action provided very few buy points on the breakouts. Latest low was in late August, when price bounced at $26.38. Like in all uptrends, price needs to take breath and currently price is consolidating the gains in a range between $33.01 and $26.38
Moving averages are simple indicators for traders to gauge direction. A moving average is calculated as the simple mean of the previous N periods (usually sessions). Usual time periods used for moving averages are 21 days, 50 days, 100 days and 200 days. Further about Moving Averages from sources like Wikipedia and Investopedia
Investors use support and resistance levels to spot price points in the stock price action that tend to act as glass ceiling, preventing the price of shares to move up or down. Supports are levels where the price tends to stop as it falls. Price is more likely to "bounce off" this level rather than break through it. However, if the price breaks down the support, it is likely to continue declining until meeting another support level. On the other hand, resistances are where the price tends to find opposition as it moves up. Likewise, this means that the price is more likely to "bounce off" at this level, and if it finally crosses this level, the price will climb easily until it hits the next resistance
The current resistances are:
The current supports are:
This is an indicator that was introduced in the 1980s by John Bollinger. Essentially, the Bollinger Bands are lines that fluctuate around a centralmoving averagediffering in distance from the bottom to the top depending on market volatility. They are usually drawn by an offset of two standard deviations, above and below, from a moving average line. Bollinger himself recommends the moving average period to be 20
The RSI (Relative Strength Index) is an oscillator-type indicator that measures price fluctuations to spot when the share or financial asset is oversold or overbought. Like other oscillation indicators, the RSI moves in a range from 0% to 100%. The relative strength indicator is one of the best known and most widely used indicators, and it was invented by J. Welles Wilder in 1978
The RSI has been between the overbought and oversold zones for many weeks, and therefore, without this indicator really being of any help to us in making any decisions.
Apellis Pharmaceuticals, Inc. (APLS) published Q2 earnings of $-1.57 per share, grossly failing to match the analysts consensus estimate of $-1.33 per share. This Q2 report represents an earnings surprise of -18.05%. On the contrary, reported sales were $0.00, consistent with the market estimates.
Compared to the same quarter last year, EPS was $-1.12, so posted EPS is a decrease of -40.18%. Looking at turnover, figures just changed compared to $0.00 same quarter last year.
APLS is hosting the Q3 earnings call on early next November. Expected EPS for this quarter is $-1.58. Financial reporting day has a more than usual risk for stock traders as the information posted can soar and sink the price with lower volume and not respecting your buy/stop-loss orders. Have a look company's website to confirm time and details about the earnings call and the earnings report.